Halozyme Therapeutics, Inc. (HALO)
$5.75
-0.23 (-3.85%)
| CAPS Rating |
|
|---|---|
| Open | $5.89 |
| Previous Close | $5.98 |
| Daily Range | $5.75 - $5.98 |
| 52-Week Range | $2.60 - $8.09 |
| Market Cap | $526.97M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 226,925 |
| Average Daily Volume | 390,000 |
HALO
VS S&P 500 (SPY)
How do you think HALO will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
HALO Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
HALO News and Commentary
- CNBC on Halozyme Therapeutics, Inc. – Ockham-RazorWire
- CNBC on Halozyme Therapeutics, Inc. – Ockham-RazorWire
- Miss the Recent Market Bottom? – The Motley Fool
- 6 Stocks Defying the Doubters – The Motley Fool
Related News and Articles
- Dream Stocks for Biotech Investors – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 4 Platform Drugmakers to Invest In – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- A Big Upgrade for Allos Therapeutics – The Motley Fool
- Now's a Great Time to Invest -- So Don't Blow It Like This – The Motley Fool
- This Stock Is a Train Wreck – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- The Hottest Sector for 2010 – The Motley Fool
- Abbott: Brave or Stupid? – The Motley Fool
- 5-Star Stocks Poised to Pop: American Oriental Bioengineering – The Motley Fool
- Do You Have the Guts to Buy? – The Motley Fool
- This Top Stock Is a Winner – The Motley Fool
RSS Headlines
Fool UK
